调强放疗联合乙酰半胱氨酸治疗非小细胞肺癌的疗效观察

doi:10.3969/j.issn.1671-7171.2019.01.007

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To explore the clinical efficacy of intensity-modulated radiation therapy combined with acetylcysteine in the treatment of non-small cell lung cancer (NSCLC).【Methods】 In this study, a total of 80 patients with NSCLC admitted in our hospital from August 2014 to December 2015, were divided into two groups on the basis of random number table method, with 40 cases in each group. The control group was administrated with solely intensity-modulated radiation therapy, while the treatment group was administrated with intensity-modulated radiation therapy in combination with acetylcysteine. The incidence of radiation pneumonitis, changes of serum biological markers [glutathione (GSH), interleukin (IL) -6, transforming growth factor (TGF) -β, type II alveolar cell surface antigen (KL-6)], and Karnofsky performance status (KPS) scores at different time points before and after the therapy were compared between the two groups.【Results】 The incidence of radiation pneumonitis in the treatment group was 15.00% (6/40), which was significantly lower than that in the control group 40.00% (16/40)(P<0.05). The serum GSH levels in the observation group at the end of radiotherapy and 1 and 3 months after radiotherapy were significantly higher than those in the control group. The serum levels of IL-6, TGF-β and KL-6 were significantly lower than those in the control group (P<0.05). The KPS scores at the end of radiotherapy and 1 and 3 months after radiotherapy were significantly increased in the observation group compared with the control group (P<0.05).【Conclusion】 In the treatment of NSCLC, the combination of intensity modulated radiation therapy and acetylcysteine proves to be effective in preventing radiation pneumonitis, enhancing body's antioxidation capacity, reducing the irradiation-induced lung injury and improving life quality.

Key words： Lung Neoplasms/RT Pharmaceutical Preparations

Received: 10 July 2018

PACS:

R734.2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2019.01.007 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2019/V36/I1/21

[1] 王绿化,傅小龙,陈明,等.放射性肺损伤的诊断及治疗[J].中华放射肿瘤学杂志,2015,24(1):4-9.
[2] Dunning JR, Trella JD, Osterhoudt KC. A novel oral formulation of N-acetylcysteine [J]. Pediatr Emerg Care, 2016, 32 (9): 652.
[3] 张俊伶,路璐,李德冠,等.N-乙酰半胱氨酸对辐射致小鼠骨髓单个核细胞损伤的保护作用[J].天津医药,2014,42(1):54-57.
[4] 汤钊猷.现代肿瘤学[M].上海:复旦大学出版社,2011:100-115.
[5] 姜潮.常见肿瘤规范病历质控标准及书写指南[M].北京:北京大学医学出版社,2006:191.
[6] Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) [J]. Int J Radiat Oncol Biol Phys, 1995, 31 (5): 1341-1346.
[7] Palma DA, Senan S, Tsujino K, et al. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis [J]. Int J Radiat Oncol Biol Phys, 2013, 85 (2): 444-450.
[8] 王一,赵彤,凌云,等.中西医防治放射性肺炎的研究进展[J].时珍国医国药,2016,35(11):2719-2721.
[9] 孙科远,李聪,吴晗,等.N-乙酰半胱氨酸对慢性阻塞性肺疾病急性加重期患者血清氧化物质水平的影响研究[J].实用心脑肺血管病杂志,2016,24(1):141-143.
[10] Rostami AR, Sharifi M, Kamali AR, et al. Evaluation of the effect of combination of n-acetylcysteine and vitamin c on improving outcomes following CABG [J]. Chest, 2016, 117 (3): 662-671.
[11] 韦嵩,蒙如闯,张发恩.肺癌放射治疗致放射性肺炎的相关因素分析[J].癌症进展,2016,14(3):269-271.
[12] 刘勇.N-乙酰半胱氨酸对老年慢性阻塞性肺疾病患者免疫功能及细胞因子的影响[J].现代中西医结合杂志,2017,26(17):1880-1882.
[13] Luo F, Zhuang Y, Sides MD, et al. Arsenic trioxide inhibits transforming growth factor - β1 - induced fibroblast to myofibroblast differentiation in vitro and bleomycin induced lung fibrosis in vivo [J]. Respir Res, 2014, 15 (1): 51.
[14] 王静,贾敬好,杨海芳,等.非小细胞肺癌放疗前后血清TGF-β1水平测定的临床意义[J].河北医科大学学报,2017,38(6):654-658.